Medical/Pharmaceuticals
Chugai Pharma Taiwan wins Social Empowerment and Green Leadership Categories at the Asia Responsible Enterprise Awards 2024
SINGAPORE, Sept. 4, 2024 /PRNewswire/ -- The Asia Responsible Enterprise Awards (AREA) 2024 honored Chugai Pharma Taiwan as an outstanding business leader that champions sustainable and responsible business practices. Presented by leading regional NGO Enterprise Asia, the AREA ceremony was held i...
The Vietnam Small Animal Veterinary Association (VSAVA) and South Korea's NEL Animal Medical Foundation have joined forces to strengthen international cooperation in veterinary medicine
HO CHI MINH, Vietnam, Sept. 5, 2024 /PRNewswire/ -- Saigon Ventures Co., Ltd. facilitated the signing of a Memorandum of Understanding (MOU) betweenSouth Korea's NEL Animal Medical Foundation (formerly NEL Animal Medical Center) and the Vietnam Small Animal Veterinary Association (VSAVA) to promo...
Veeva Vault CRM Suite to Unlock Greater Customer Centricity with Launch of Service Center
Expanded suite to unify sales, marketing, medical and service through a
connected software and data foundation
SINGAPORE, Sept. 5, 2024 /PRNewswire/ -- Veeva Systems
Accorto Regulatory Solutions joins GINN to Further Tobacco Harm Reduction Mission
RICHMOND, Va., Sept. 4, 2024 /PRNewswire/ -- Accorto Regulatory Solutions, an industry-leading regulatory compliance firm specializing in helping organizations bring their innovative FDA-regulated products to market, is proud to formally announce its membership in the Global Institute for Novel N...
Carterra unveils its most sensitive biosensor platform; Carterra Ultra™ ushers in a new frontier in fragment and small molecule drug discovery
The new instrument enables high-throughput small and large molecule characterization in traditional and AI-driven workflows SALT LAKE CITY, Sept. 4, 2024 /PRNewswire/ -- Carterra Inc., the world leader in innovative technologies enabling high-throughput biology, today has launched Carterra Ultra...
TraceLink's Magnum Release of its Opus Platform Will Revolutionize Supply Chain Management by Enabling All Businesses to Digitalize their End-to-End Supply Networks
With real-time information from all supply chain partners, Supply Chain Managers can reduce inventory and stock-out while improving service levels and lead times BOSTON, Sept. 4, 2024 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the ...
Regenity Biosciences Receives Regulatory Approval for Collagen Dental Membrane in China After First-of-its-Kind Breakthrough Clinical Study
Multicenter Clinical Study Demonstrates Benefits of Regenity's Novel Crosslinked Collagen Membrane Compared to Geistlich Bio-Gide® Collagen Membrane and Enables Launch intoChina PARAMUS, N.J., Sept. 4, 2024 /PRNewswire/ -- Regenity Biosciences, a global leader in regenerative medicine and Linden...
Phesi Receives Frost & Sullivan's Global Enabling Technology Leadership Award for Revolutionizing Clinical Development with Its Trial Accelerator Platform
Phesi's Trial Accelerator™ Platform empowers trial sponsors to make informed decisions swiftly, expediting drug development timelines while upholding the highest standards of data integrity and patient-centricity SAN ANTONIO, Sept. 4, 2024 /PRNewswire/ -- Frost & Sullivan has recognized Phesi wi...
LakeShore Biopharma Announces Leadership Transitions
GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...
21st.BIO obtains self-affirmed GRAS status for its precision fermented beta-lactoglobulin: 21st.BIO customers can now enter the U.S. market with their own production using 21st.BIO technology
* 21st.BIO has earned a self-affirmed GRAS status for its animal-free beta-lactoglobulin ingredient, which customers can now launch inthe United States market. * 21st.BIO is helping customers bring products to market at an unprecedented pace, from initiation of development to market approval ...
Innovent Receives Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α Bispecific Antibody Fusion Protein) as Monotherapy for Advanced Melanoma
SAN FRANCISCO and SUZHOU, China, Sept. 4, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
MELBOURNE, Australia, Sept. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company's IPAX-1 Phase I study has been published inNeuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 thera...
Frost Radar™ Positions 14 Top Growth & Innovation Leaders in Global Healthcare Data Interoperability
Frost & Sullivan's Benchmarking System Highlights Leading Companies Poised for Growth and Advancing Healthcare Interoperability SAN ANTONIO, Sept. 4, 2024 /PRNewswire/ -- The healthcare data interoperability market is expected to reach$19.28 billion by 2028, growing at a compound annual growth ...
Neusoft Education Actively Advances Education-Healthcare-Wellness Integrated Development, Starting a New Horizon for High-Quality Development
HONG KONG, Aug. 29, 2024 /PRNewswire/ -- Neusoft Education Technology Co. Limited (Stock code: 9616.HK, "Neusoft Education" or "the Group") announced its interim results for 2024. In 2024, the Group strategically expanded its elderly education and healthcare and wellness services on the basis of ...
Seegene and Springer Nature Launch 'Nature Awards MDx Impact Grants' to Innovate Syndromic PCR Diagnostic Assays
- Nature Awards MDx Impact Grants in partnership with Seegene extends commitment to external innovation. - Global research teams invited to submit proposals to develop new tests for human infectious diseases. Application deadline:December 2, 2024. - Nature Awards to lead the application and eva...
Frost & Sullivan Released Report: "BiBo Pharma: A Global CDMO Leading in Advanced Biopharmaceutical Manufacturing Technologies"
SHANGHAI, Sept. 2, 2024 /PRNewswire/ -- Frost & Sullivan released a report, titled "BiBo Pharma: A Global CDMO Leading in Advanced Biopharmaceutical Manufacturing Technologies". The report explores a global CDMO leading the "The Fourth Revolutionary Wave of Biologics Manufacturing" and pioneering...
Innovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024
SAN FRANCISCO and SUZHOU, China, Sept. 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
ThinkCyte Secures $32 million in Series C Funding to Drive Global Expansion of VisionSort™
TOKYO and REDWOOD CITY, Calif., Aug. 31, 2024 /PRNewswire/ -- ThinkCyte today announced the successful completion of its Series C funding round. Including the equity financingsecured last November, the company raised an additional $15 million in the extension round, bringing the total to $32 mill...
LifeTech Scientific Corporation Announced 2024 Interim Results: International Business Increased by 30%, Net Profit Margin Attributable to Owners of the Company Reached 35.8%
SHENZHEN, China, Aug. 30, 2024 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "LifeTech", Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiarie...
Pierre Fabre Laboratories receives European Commission Approval for BRAFTOVI®(encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation
* European approval is based on results from the Phase II PHAROS trial, which showed a meaningful clinical benefit to BRAFV600E mutated advanced NSCLC patients with an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients.[1-3] The safety profil...
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00